Novartis AG with ticker code (NVS) now have 5 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 108 and 100 calculating the mean target price we have 104.4. Now with the previous closing price of 88.27 this would indicate that there is a potential upside of 18.3%. There is a 50 day moving average of 87.73 and the 200 day MA is 86.6. The market capitalisation for the company is $190,748m. You can visit the company’s website by visiting: https://www.novartis.com
The potential market cap would be $225,605m based on the market concensus.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
